Evolutionary trajectories of myelodysplastic syndromes/neoplasms
Seminars in Cancer Biology · 2026
DOI: 10.1016/j.semcancer.2026.01.006 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Seminars in Cancer Biology, 2026. Verfasst von Maria Creignou und 3 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris-Saclay, Gustave Roussy, Inserm UMR 1361 Cancer Data Science, IHU PRISM National PRecISion Medicine Center in Oncology, Villejuif F-9…. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 190 Literaturangaben. Gefördert von: Dr Åke Olssons Stiftelse för Haematologisk Forskning, Edward P Evans Foundation, Cancerfonden.
Abstract (Originalsprache)
Myelodysplastic syndromes/neoplasms (MDS) are a heterogeneous group of myeloid malignancies characterized by clonality, cytopenia, bone marrow dysplasia, and a variable risk of progression to acute myeloid leukemia (AML). With few therapeutic advances beyond the introduction of hypomethylating agents twenty years ago, MDS remains associated with poor overall survival, limited curative options, and frequent relapse or resistance to available treatments. Breakthroughs in genomic and single-cell technologies have transformed our understanding of MDS pathogenesis, revealing that disease initiation and progression follow stereotyped evolutionary trajectories driven by distinct constellations of somatic mutations and modulated by both endogenous and exogenous factors. In this review, we synthesize current knowledge of the genetic landscape of MDS and dissect the clonal path of the disease from precursor states to AML transformation. We further discuss how germline predisposition, bone marrow microenvironmental remodeling, and exposure to environmental or genotoxic stressors impact the selection, expansion, and transformation potential of the hematopoietic clone. Finally, we outline how these insights have underpinned a conceptual shift toward a molecular taxonomy of myeloid neoplasms, redefining diagnostic boundaries between MDS and AML, improving prognostic stratification, and enabling a biology-driven framework for personalized treatment of MDS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Université Paris-Saclay, Gustave Roussy, Inserm UMR 1361 Cancer Data Science, IHU PRISM National PRecISion Medicine Center in Oncology, Villejuif F-94805, France; Department of Medicine Huddinge, Karolinska Institutet,…
- Department of Molecular Medicine, University of Pavia, Unit of Molecular Hematology and Precision Medicine, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy.
- Université Paris-Saclay, Gustave Roussy, Inserm UMR 1361 Cancer Data Science, IHU PRISM National PRecISion Medicine Center in Oncology, Villejuif F-94805, France. Electronic address: elsa.bernard@gustaveroussy.fr.
- Department of Molecular Medicine, University of Pavia, Unit of Molecular Hematology and Precision Medicine, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy. Electronic address: luca.malcovati@unipv.it.
Förderung
- Dr Åke Olssons Stiftelse för Haematologisk Forskning
- Edward P Evans Foundation
- Cancerfonden
- Svenska Läkaresällskapet
- Sardinian Association for Research on Gynaecological Oncology
- Associazione Italiana per la Ricerca sul Cancro
- Institut National de la Santé et de la Recherche Médicale
- French National Research Agency
Zitieren
APA
Creignou, M., Sarchi, M., Bernard, E., & Malcovati, L. (2026). Evolutionary trajectories of myelodysplastic syndromes/neoplasms. Seminars in Cancer Biology. https://doi.org/10.1016/j.semcancer.2026.01.006
Vancouver
Creignou M, Sarchi M, Bernard E, Malcovati L. Evolutionary trajectories of myelodysplastic syndromes/neoplasms. Seminars in Cancer Biology. 2026. doi:10.1016/j.semcancer.2026.01.006
BibTeX
@article{Creignou2026,
author = {Creignou, Maria and Sarchi, Martina and Bernard, Elsa and Malcovati, Luca},
title = {Evolutionary trajectories of myelodysplastic syndromes/neoplasms},
journal = {Seminars in Cancer Biology},
year = {2026},
doi = {10.1016/j.semcancer.2026.01.006}
}
EUVIMED